KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Depreciation & Amortization (CF) (2016 - 2025)

Neogenomics (NEO) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 10.83% year-over-year to $8.8 million, compared with a TTM value of $36.1 million through Dec 2025, down 7.75%, and an annual FY2025 reading of $36.1 million, down 7.75% over the prior year.
  • Depreciation & Amortization (CF) was $8.8 million for Q4 2025 at Neogenomics, roughly flat from $8.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $9.9 million in Q1 2024 and bottomed at $6.7 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.9 million, with a median of $9.1 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) rose 25.67% in 2022, then decreased 10.83% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $8.4 million in 2021, then increased by 13.04% to $9.5 million in 2022, then rose by 1.06% to $9.6 million in 2023, then grew by 2.6% to $9.8 million in 2024, then fell by 10.83% to $8.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for NEO at $8.8 million in Q4 2025, $8.8 million in Q3 2025, and $9.1 million in Q2 2025.